MEDIMMUNE AND ALKERMES SIGN AGREEMENT TO DEVELOP
 PULMONARY DELIVERY SYSTEM FOR MONOCLONAL ANTIBODY AGAINST RESPIRATORY
SYNCYTIAL VIRUS

Gaithersburg,  MD and Cambridge,  MA, June 13, 2000 -- MedImmune,  Inc. (NASDAQ:
MEDI) and Alkermes, Inc. (NASDAQ: ALKS) announced today that they have signed an
agreement to develop an inhalable formulation of a monoclonal antibody targeting
the  respiratory  syncytial  virus (RSV) using Alkermes  AIR(TM)  pulmonary drug
delivery technology.

Under the terms of the  agreement,  MedImmune  receives an exclusive,  worldwide
license to products produced by the  collaboration,  while Alkermes will receive
certain initial fees,  development  funding,  milestone payments,  manufacturing
fees,  and  royalties  on product  sales.  Alkermes is  responsible  for product
formulation  and pulmonary  delivery device  development and commercial  supply.
MedImmune  is  responsible  for  clinical  development,   bulk  product  supply,
regulatory approval and worldwide marketing.

"We look  forward to working  with  Alkermes  to develop an  inhalable  delivery
system for use in preventing RSV in adult  populations at risk of infection with
the  virus,"  said Dr.  Wayne  T.  Hockmeyer,  MedImmune's  chairman  and  chief
executive officer.  "Alkermes' AIR technology is impressive and presents several
characteristics that should prove beneficial for our particular needs."

"We are pleased to be working  with  MedImmune  for the delivery of a monoclonal
antibody  to the  lung,"  said  Richard  F.  Pops,  Chief  Executive  Officer of
Alkermes.  "This  represents an exciting  opportunity in pulmonary drug delivery
and we are  delighted  to be  adding a company  of  MedImmune's  stature  to our
outstanding group of collaborators."

Alkermes' AIR drug  delivery  system is based on a novel  concept,  published in
Science magazine in 1997, that relatively large,  low-density drug particles can
be inhaled  into the lungs with high  efficiency  from simple  inhaler  devices.
These particles have distinct  physical  characteristics  with several potential
advantages over other  inhalation  delivery  systems.  The AIR system utilizes a
small,  convenient  delivery device; can deliver a wide range of drug doses; and
has the potential to provide sustained release delivery of drugs.

Alkermes, Inc. is a leader in the development of products based on sophisticated
drug delivery technologies.  The company has several areas of focus: controlled,
sustained  release of injectable  drugs lasting  several days to several  weeks,
utilizing its  ProLease(R)  and  Medsorb(R)  technologies;  the  development  of
pharmaceutical   products   based  on   proprietary   pulmonary   drug  delivery
technologies  utilizing  its AIR  technology;  oral  delivery of drugs using the
RingCap(TM) and DST technologies;  and the delivery of drugs into the brain past
the blood-brain barrier,  utilizing its Cereport(R)  technology.  In addition to
its   Cambridge,   Massachusetts   headquarters,   research  and   manufacturing
facilities,  Alkermes operates research and manufacturing facilities in Ohio and
a medical affairs office in Cambridge, England.

MedImmune,   Inc.  is  a  fully  integrated  biotechnology  company  focused  on
developing  and marketing  products that address  medical needs in areas such as
infectious disease, immune regulation and cancer. Headquartered in Gaithersburg,
Maryland,  MedImmune has  manufacturing  facilities  in Frederick,  Maryland and
Nijmegen,  the  Netherlands,  and an oncology  subsidiary in West  Conshohocken,
Pennsylvania.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a  number  of  factors,  including  risks  and  uncertainties  discussed  in the
companies' filings with the U.S. Securities and Exchange  Commission.  MedImmune
cautions that RSV disease occurs primarily during the winter months; the company
believes its operating results will reflect that seasonality for the foreseeable
future.  The company is also developing  several  products for potential  future
marketing. There can be no assurance that such development efforts will succeed,
that such products will receive required  regulatory  clearance or that, even if
such regulatory clearance were received,  such products would ultimately achieve
commercial success.

                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereonto duly authorized.

                                 MEDIMMUNE, INC.
                                -----------------
                                  (Registrant)

June 14, 2000 By:

                           ---------------------------
                          David M. Mott, Vice Chairman
                           and Chief Financial Officer
[{"type": "8-K", "sequence": "1", "filename": "0001.txt", "description": "MEDIMMUNE AND ALKERMES SIGN AGREEMENT", "secsgml_size_bytes": 5177}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14657", "film-number": "656128"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
MEDIMMUNE AND ALKERMES SIGN AGREEMENT TO DEVELOP
 PULMONARY DELIVERY SYSTEM FOR MONOCLONAL ANTIBODY AGAINST RESPIRATORY
SYNCYTIAL VIRUS

Gaithersburg,  MD and Cambridge,  MA, June 13, 2000 -- MedImmune,  Inc. (NASDAQ:
MEDI) and Alkermes, Inc. (NASDAQ: ALKS) announced today that they have signed an
agreement to develop an inhalable formulation of a monoclonal antibody targeting
the  respiratory  syncytial  virus (RSV) using Alkermes  AIR(TM)  pulmonary drug
delivery technology.

Under the terms of the  agreement,  MedImmune  receives an exclusive,  worldwide
license to products produced by the  collaboration,  while Alkermes will receive
certain initial fees,  development  funding,  milestone payments,  manufacturing
fees,  and  royalties  on product  sales.  Alkermes is  responsible  for product
formulation  and pulmonary  delivery device  development and commercial  supply.
MedImmune  is  responsible  for  clinical  development,   bulk  product  supply,
regulatory approval and worldwide marketing.

"We look  forward to working  with  Alkermes  to develop an  inhalable  delivery
system for use in preventing RSV in adult  populations at risk of infection with
the  virus,"  said Dr.  Wayne  T.  Hockmeyer,  MedImmune's  chairman  and  chief
executive officer.  "Alkermes' AIR technology is impressive and presents several
characteristics that should prove beneficial for our particular needs."

"We are pleased to be working  with  MedImmune  for the delivery of a monoclonal
antibody  to the  lung,"  said  Richard  F.  Pops,  Chief  Executive  Officer of
Alkermes.  "This  represents an exciting  opportunity in pulmonary drug delivery
and we are  delighted  to be  adding a company  of  MedImmune's  stature  to our
outstanding group of collaborators."

Alkermes' AIR drug  delivery  system is based on a novel  concept,  published in
Science magazine in 1997, that relatively large,  low-density drug particles can
be inhaled  into the lungs with high  efficiency  from simple  inhaler  devices.
These particles have distinct  physical  characteristics  with several potential
advantages over other  inhalation  delivery  systems.  The AIR system utilizes a
small,  convenient  delivery device; can deliver a wide range of drug doses; and
has the potential to provide sustained release delivery of drugs.

Alkermes, Inc. is a leader in the development of products based on sophisticated
drug delivery technologies.  The company has several areas of focus: controlled,
sustained  release of injectable  drugs lasting  several days to several  weeks,
utilizing its  ProLease(R)  and  Medsorb(R)  technologies;  the  development  of
pharmaceutical   products   based  on   proprietary   pulmonary   drug  delivery
technologies  utilizing  its AIR  technology;  oral  delivery of drugs using the
RingCap(TM) and DST technologies;  and the delivery of drugs into the brain past
the blood-brain barrier,  utilizing its Cereport(R)  technology.  In addition to
its   Cambridge,   Massachusetts   headquarters,   research  and   manufacturing
facilities,  Alkermes operates research and manufacturing facilities in Ohio and
a medical affairs office in Cambridge, England.

MedImmune,   Inc.  is  a  fully  integrated  biotechnology  company  focused  on
developing  and marketing  products that address  medical needs in areas such as
infectious disease, immune regulation and cancer. Headquartered in Gaithersburg,
Maryland,  MedImmune has  manufacturing  facilities  in Frederick,  Maryland and
Nijmegen,  the  Netherlands,  and an oncology  subsidiary in West  Conshohocken,
Pennsylvania.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a  number  of  factors,  including  risks  and  uncertainties  discussed  in the
companies' filings with the U.S. Securities and Exchange  Commission.  MedImmune
cautions that RSV disease occurs primarily during the winter months; the company
believes its operating results will reflect that seasonality for the foreseeable
future.  The company is also developing  several  products for potential  future
marketing. There can be no assurance that such development efforts will succeed,
that such products will receive required  regulatory  clearance or that, even if
such regulatory clearance were received,  such products would ultimately achieve
commercial success.

                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereonto duly authorized.

                                 MEDIMMUNE, INC.
                                -----------------
                                  (Registrant)

June 14, 2000 By:

                           ---------------------------
                          David M. Mott, Vice Chairman
                           and Chief Financial Officer